Journal article

Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies

Heidi E Drummer

Frontiers in Microbiology | FRONTIERS MEDIA SA | Published : 2014


Despite 20 years of research, a vaccine to prevent hepatitis C virus (HCV) infection has not been developed. A vaccine to prevent HCV will need to induce broadly reactive immunity able to prevent infection by the 7 genetically and antigenically distinct genotypes circulating world-wide. HCV encodes two surface exposed glycoproteins, E1 and E2 that function as a heterodimer to mediate viral entry. Neutralizing antibodies (NAbs) to both E1 and E2 have been described with the major NAb target being E2. The function of E2 is to attach virions to host cells via cell surface receptors that include, but is not limited to, the tetraspanin CD81 and scavenger receptor class B type 1. However, E2 has d..

View full abstract

University of Melbourne Researchers


Awarded by NHMRC and its Independent Research Institute Infrastructure Support Scheme

Funding Acknowledgements

Heidi E. Drummer is supported by NHMRC senior research fellowship 1041897 and its Independent Research Institute Infrastructure Support Scheme. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.